Sanofi-Synthelabo/Organon Arixtra
Executive Summary
Antithrombotic agent Arixtra (fondaprinux) is designated "approvable" by FDA ahead of Aug. 15 priority review deadline. The NDA seeks an indication for the prevention of venous thromboembolic events following orthopedic surgery